Cannabis and schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Mcloughlin, Benjamin C ^a   Pushpa Rajah, Jonathan A ^a   Gillies, Donna ^b   Rathbone, John ^c   Variend, Hannele ^d   Kalakouti, Eliana ^e   Kyprianou, Katerina ^e  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b CUMBERLAND HOSPITAL   (Australia)

^c BOND UNIVERSITY   (Australia)

^d Becklin Centre   (United Kingdom)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; CANNABIS; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; MEDICAL CANNABIS; SULPIRIDE; SULTOPRIDE;

BRIEF PSYCHIATRIC RATING SCALE; CANNABIS ADDICTION; DRUG EFFECT; FOLLOW UP; HUMAN; MENTAL HEALTH; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOSIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; MARIJUANA ABUSE; META ANALYSIS; PSYCHOLOGY;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CANNABINOIDS; HUMANS; MARIJUANA ABUSE; MEDICAL MARIJUANA; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA; SULPIRIDE;

EID: 84921956029     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004837.pub3     Document Type: Review

References (119)

1. Akerele E, Levin FR. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. American Journal on Addictions 2007;16(4):260-8. [MEDLINE: 17661193].
2. Bonsack C, Gibellini Manetti S, Favrod J, Montagrin Y, Besson J, Bovet P, et al.Motivational intervention to reduce cannabis use in young people with psychosis: randomised control trial. Psychotherapy and Psychosomatics 2011;80(5):287-97.
3. Brunette MF, Dawson R, O'Keefe CD, Narasimhan M, Noordsy DL, Wojcik NJ, et al.A randomized trial of clozapine versus other antipsychotics for cannabis use disorder in patients with schizophrenia. Journal of Dual Diagnosis 2011;7(1-2):50-63.
4. Edwards J. Early psychosis service developments: becoming real. 3rd International Conference on Early Psychosis; 2002 Sep 25-28; Copenhagen, Denmark. 2002:56. [: KA03].
5. Edwards J, Elkins K, Hinton M, Harrigan SM, Donovan K, Athanasopoulos O, et al.Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatrica Scandinavica 2006;114(2):109-17. [MEDLINE: 16836598].
6. Edwards J, Elkins KS, Hinton MF, Harrigan SM, Donovan KD, Athanasopoulos O. Randomized controlled trial of a cannabis-focused intervention versus psychoeducation for young people continuing to use cannabis in the 12 months following entry to treatment for first-episode psychosis. Schizophrenia Research 2004;70(1):61. [: ISI:000224551100164].
7. Hjorthj CR, Fohlmanna A, Larsena AM, Gluuda C, Arendta M, Nordentoft M. Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomised trial. Psychological Medicine July 2013;43(7):1499-510.
8. Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al.Cannabidiol enhances anandamide signalling and alleviates psychotic symptoms of schizophrenia. Translation Psychiatry 2012;2(94):1-7.
9. Madigan K, Brennan D, Lawlor E, Turner N, Kinsella A, O'Connor JJ, et al.A multi-center, randomized control trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of the illness. Schizophrenia research 2013;143(1):138-42.
10. van Nimwegen L, de Haan L, van Beveren N, Laan W, van de Brink W, Linszen D. Subjective well-being and craving for cannabis in first psychosis, a randomized double blind comparison of olanzapine vs risperidone. Canadian Jourmal of Psychiatry 2008;53(6):400-5.
11. Baker A, Bucci S, Lewin TJ, Kay-Lambkin F, Constable PM, Carr VJ. Cognitive behavioural therapy for substance use disorders in people with psychotic disorders. British Journal of Psychiatry 2006;188:439-48.
12. Barrowclough C, Haddock G, Wykes T, Beardmore R, Conrod P, Craig T, et al.Integrated motivational interviewing and cognitive behavioural therapy for people with psychosis and comorbid substance misuse: randomised controlled trial. BMJ 2010;341:c6325.
13. Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y. A randomized clinical trial of a new behavioural treatment for drug abuse in people with severe and persistent mental illness. Archives of General Psychiatry 2006;63(4):426-32.
14. James W, Preston NJ, Koh G, Spencer C, Kisely SR, Castle DJ. A group intervention which assists patients with dual diagnosis reduce their drug use: a randomised control trial. Psychological Medicine 2004;34(6):983-90.
15. Kemp R, Harris A, Vurel E, Sitharthan T. Stop using stuff: trial of a drug and alcohol intervention for young people with comorbid mental illness and drug and alcohol problems.. Australasian psychiatry 2007;15(6):490-3.
16. Matrino S, Carroll KM, Nich C, Rounsaville BJ. A randomised controlled pilot study of motivational interviewing for patients with psychotic and drug use disorders. Addiction 2006;101(10):1479-92.
17. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al.Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 2005;57(6):594-608.
18. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: The Calgary Depression Scale. British Journal of Psychiatry 1993;163(22):39-44.
19. Allebeck P, Adamsson C, Engström A. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Acta Psychiatrica Scandinavica 1993;88(1):21-4.
20. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
21. Andreasen NC. Negative symptoms in schizophrenia. Archives of General Psychiatry 1983;39:784-8.
22. Andreasen NC. The Scale for the Assessment of Positive Symptoms(SAPS). University of Iowa. Iowa City, Iowa 1984.
23. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet 1987;2:1483-6.
24. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffit TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002;325:1212-3.
25. Ashton CH. Pharmacology and effects of cannabis: a brief review. British Journal of Psychiatry 2001;178:101-6.
26. Baigent M, Holme G, Hafner RJ. Self reports of the interaction between substance abuse and schizophrenia. Australian and New Zealand Journal of Psychiatry 1995;29(1):69-74.
27. Beck AT, Beck RW. Screening depressed patients in family practice. A rapid technique. Postgraduate Medicine 1972;52:81-5.
28. Berridge V. Cannabis Britannica: Empire, trade and prohibition. English Historical Review 2004;483:1075-175.
29. Bersani G, Orlandi V, Kotzalidis GD, Pancheri P. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. European Archives of Psychiatry and Clinical Neuroscience 2002;252(2):86-92.
30. Birchwood M, Smith J, Cochrane R. Specific and non-specific effects of educational intervention for families living with schizophrenia. A comparison of three methods. British Journal of Psychiatry 1992;160:806-14.
31. Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M. A self-report Insight scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatrica Scandinavica Jan 1994;89(1):62-7.
32. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
33. Bodlund O, Kullgren G, Ekselius L. Axis V - Global Assessment of Functioning Scale. Evaluation of a self-report version. Acta Psychiatrica Scandinavica November 1994;90(5):342-7.
34. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al.The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
35. Carney M, Bacelle L, Robinson B. Psychosis after cannabis use. BMJ 1984;288:1047.
36. Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
37. Casadioa P, Fernandes C, Murray RM, Di Forti M. Cannabis use in young people: the risk for schizophrenia. Neuroscience and biobehavioral reviews 2011;35(8):1779-87.
38. Chopra GS, Smith JW. Psychotic reactions following cannabis use in East Indians. Archives of General Psychiatry 1974;30:24-7.
39. Condren RM, O'Connor J, Browne R. Prevalence and patterns of substance misuse in schizophrenia. A catchment area case-control study. Psychiatric Bulletin 2001;25(1):17-20.
40. D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. European Archives of Psychiatry Clinical Neuroscience 2009;259(7):413-31.
41. Davison K, Wilson H. Psychosis associated with cannabis smoking. Addiction 1972;67(3):225-8.
42. Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. 2000.
43. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
44. Dixon L, Haas G, Wedien PJ, Sweeney J, Frances AJ. Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports. Schizophrenia Bulletin 1990;16:69-79.
45. Donner A, Klar N. Issues in the meta-analysis of cluster randomised trials. Statistics in Medicine 2002;21:2971-80.
46. Duke PJ, Pantelis C, McPhillips MA, Barnes TR. Comorbid non-alcohol substance misuse among people with schizophrenia: epidemiological study in central London. British Journal of Psychiatry 2001;179:509-13.
47. Egger M, Davey G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
48. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
49. An overview of drug potency in Europe. European Monitoring Centre for Drugs and Drug Addiction.
50. Farrell M, Howes C, Taylor C. Substance misuse of psychiatric co-morbidity: an overview of the OPCS National Psychiatric Morbidity Survey. Addictive Behavior 1998;23:908-18.
51. Franken IH, Hendriks VM, Van den Brink W. Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire.. Addictive Behaviors, 2002;27(5):675-85.
52. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signalling. Physiological reviews Jul 2003;83(3):1017-66.
53. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
54. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society 1964;86:1646-7.
55. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. American Journal of Pschiatry 1992;149:1148-56.
56. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
57. Hall W, Johnston L, Donnelly N. The Health Effects of Cannabis. 1st Edition. Toronto: Toronto: Additction Research Foundation, 1999.
58. Hambrecht M, Häfner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Australian and New Zealand Journal of Psychiatry 2000;34(3):468-75.
59. Heishman SJ, Singleton EG. Assessment of cannabis craving using the Marijuana Craving Questionnaire. Methods in Molecular Medicine 2006;123:209-16.
60. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, et al.Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005;330(11):7481.
61. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM. Gene-environment interplay between cannabis and psychosis. Schizophrenia Bulletin 2008;34(6):1111-21.
62. Hides L, Dawe S, Kavanagh DJ, Young RM. Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. British Journal of Psychiatry 2006;189:137-43.
63. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
64. Higgins JPT. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: Higgins JPT, Green S editor(s). The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd., 2006.
65. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
66. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine Feb 1983;13(1):177-83.
67. Hunt GE, Matheson SL, Siegfried N, Walter G, Cleary M. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD001088.pub3].
68. Isbell H, Gorodetsky CW, Jasinski D, Claussen U, Spulak F, Korte F. Effects of 9-trans-tetrahydrocannabinol in man. Psychophormacologia 1967;11:184.
69. Jablensky A, Sartorius N, Ernberg G, Anker, M. Schizophrenia: manifestations, incidence and course in different cultures: A World Health Organization ten-country study. Psychological Medicine 1992;Suppl 20:97.
70. Kavanagh DJ, Waghorn G, Jenner L, Chant DC, Carr V, Evans M, et al.Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophrenia Research 2004;66(2-3):115-24.
71. Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. North Tonawanda (NY): Multi-Health Systems, 1986.
72. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13(2):261-76.
73. Kolliakoua A, Joseph C, Ismail K, Atakan Z, Murray RM. Why do patients with psychosis use cannabis and are they ready to change their use?. Neuroscience May 2011;29(3):335-46.
74. Kouri EM, Harrison G, Pope G Jnr. Changes in aggressive behavior during withdrawal from long term marijuana use. Psychopharmacology 1999;143:302-8.
75. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856].
76. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale Scores. British Journal of Psychiatry 2005;187:366-71.
77. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artefact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632].
78. Leweke FM, Guiffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999;10:1665-69.
79. Linszman DH, Dingemans PM, Lenoir ME. Cannabis abuse and the course of recent onset schizophrenic disorders. Archives of General Adult Psychiatry 1994;51:273-9.
80. Lishman WA. Organic Psychiatry: The Psychological Consequences of Cerebral Disorder. 3rd Edition. Oxford: Blackwell, 1998.
81. Littlewood R. Ideology, camouflage or contingency? Racism in British psychiatry. Transcultural Psychiatry 1988;30(3):243-90.
82. Lynskey MT, Heath AC, Nelson EC, Bucholz KK, Madden PA, Slutske WS, et al. Genetic and environmental contributions to cannabis dependence in a national young adult twin sample. Psychological Medicine 2002;32(2):195-207.
83. Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249-52.
84. Matheson SL, Shepherd AM, Laurens KR, Carr VJ. A systematic meta-review grading the evidence for non-genetic risk factors and putative antecedents of schizophrenia. Schizophrenia Research 2011;133(1-3):133-42.
85. McGovern D, Cope R. First admission rates of first and second generation Afro-Caribbeans. Journal of Social Distress and the Homeless 1987;22:139-48.
86. Mclellan A, Luborsky T, Woody L, O'Brien GE, Charles P. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. Journal of Nervous and Mental Disease 1980;168(1):26-33.
87. Miles DR, van den Bree MB, Gupman AE, Newlin DB, Glantz MD, Pickens RW. A twin study on sensation seeking, risk taking behavior and marijuana use. Drug and Alcohol Dependence 2001;62:57-68.
88. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. JAMA 2001;285(15):1987-91.
89. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al.Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370(9584):319-28.
90. Negrete JC, Knapp WP, Douglas DE, Smith WB. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychological Medicine 1986;16:515-20.
91. Nunez LA, Gurpegui M. Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiatrica Scandinavica 2002;105:173-8.
92. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacology Bulletin 1988;24:97-9.
93. Regier DA, Farmer ME, Rae DS. Co-morbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990;264:2511-8.
94. Russo EB, Jiang HE. Phytochemical and genetic analyses of ancient cannabis from Central Asia. Journal of Experimental Botany 2008;59(15):4171-82.
95. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
96. Schunemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
97. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. Journal of Psychopharmacology 2005;19(2):187-94.
98. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970;212:11-9.
99. Sinclair J. Co-morbid substance misuse in psychiatric patients: prevalence and association with length of inpatient stay. Journal of Psychopharmacology 2008;22(1):92-9.
100. Smith J, Hucker S. Schizophrenia and substance abuse. British Journal of Psychiatry 1994;165:13-21.
101. Sobell LC, Sobell MB. Timeline Follow-back: A technique for assessing self-reported ethanol consumption. In: In J. Allen, R. Z. Litten (Eds.) editor(s). Measuring Alcohol Consumption: Psychosocial and Biological Methods. Totowa, NJ: Humana Press, 1992:41-72.
102. Soyka M, Immler B, Sand P. Alcohol and drug abuse as risk factors for violence and delinquency in schizophrenic patients. Psychiatrische Praxis 1993;5:172-5.
103. Stephens RS, Roffman RA, Simpson EE. Adult marijuana users seeking treatment. Journal of Consulting and Clinical Psychology 1993;62:1100-4.
104. Talbot JA, Teague JW. Marihuana psychosis. Acute toxic psychosis associated with the use of Cannabis derivatives. JAMA 1969;210(2):299-302.
105. Tanda G, Pontiere FE, DiChiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997;276:2048-50.
106. Thomas H. A community survey of adverse effects of cannabis use. Drug and Alcohol Dependence 1996;42:201-7.
107. Tunving K. Psychiatric effects of cannabis use. Acta Psychiatrica Scandinavica 1985;72:209-17.
108. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
109. UNODC. World Drug Report 2012. United Nations publication Vol. 12, issue XI:1.
110. Van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: A longitudinal population-based study. American Journal of Epidemiology 2002;156:319-27.
111. Varma LP. Cannabis psychosis. Indian Journal of Psychiatry 1972;14:241-55.
112. Virgo N, Bennett G, Higgins D, Bennett L, Thomas P. The prevalence and characteristics of co-occurring serious mental illness (SMI) and substance abuse or dependence in the patients of Adult Mental Health and Addictions Services in eastern Dorset. Journal of Mental Health 2001;10(2):175-88.
113. Warner R. Recovery from Schizophrenia: Psychiatry and Political Economy. Psychology Press 1994.
114. Warnock J. Insanity from Hasheesh. Journal of Mental Sciences 1903;49:96-110.
115. WHOQOL. WHOQOL - Brief introduction, administration, scoring and generic version of the assessment. WHO December 1996.
116. Wing JK, Barbo T, Brugha T, Burke J, Cooper J, Giel R, et al.Schedules for Clinical Assessment in Neuropsychiatry. Archives of General Psychiatry 1990;47:589-93.
117. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al.Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
118. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BNJ 2002;325:1199-201.
119. Rathbone J, Variend H, Mehta H. Cannabis and schizophrenia. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD004837.pub2].